miRNAs as Therapeutic Tools and Biomarkers for Prostate Cancer

• Κύριοι συγγραφείς: Noemi Arrighetti (Συγγραφέας), Giovanni Luca Beretta (Συγγραφέας)
• Μορφή: Βιβλίο
• Έκδοση: MDPI AG, 2021-03-01T00:00:00Z.
• Θέματα: article
• Διαθέσιμο Online: Connect to this object online.
• Notes: 10.3390/pharmaceutics13030380; 1999-4923
• Keywords: prostate cancer; miRNA; nanodelivery; metastatic castration-resistant prostate cancer; biomarkers; Pharmacy and materia medica; RS1-441
• Source: Pharmaceutics, Vol 13, Iss 3, p 380 (2021)

Prostate cancer (PCa) is the fifth cause of tumor-related deaths in man worldwide. Despite the considerable improvement in the clinical management of PCa, several limitations emerged both in the screening for early diagnosis and in the medical treatment. The use of prostate-specific antigen (PSA)-based screening resulted in patients' overtreatment and the standard therapy of patients suffering from locally advanced/metastatic tumors (e.g., radical prostatectomy, radiotherapy, and androgen deprivation therapy) showed time-limited efficacy with patients undergoing progression toward the lethal metastatic castration-resistant PCa (mCRPC). Although valuable alternative therapeutic options have been recently proposed (e.g., docetaxel, cabazitaxel, abiraterone, enzalutamide, and sipuleucel-T), mCRPC remains incurable. Based on this background, there is an urgent need to identify new and more accurate prostate-specific biomarkers for PCa diagnosis and prognosis and to develop innovative medical approaches to counteract mCRPC. In this context, microRNA (miRNAs) emerged as potential biomarkers in prostate tissues and biological fluids and appeared to be promising therapeutic targets/tools for cancer therapy. Here we overview the recent literature and summarize the achievements of using miRNAs as biomarkers and therapeutic targets/tools for fighting PCa.